Form 4: Third Rock Ventures Sells Rapport Therapeutics Shares

Third Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. (RAPP) at a weighted average price of $40.047.

Summary

• Third Rock Ventures V, L.P. executed a sale of 18,572 shares of Rapport Therapeutics common stock.
• The transaction occurred on May 26, 2026, at a weighted average price of $40.047 per share.
• The sale was conducted pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2025.
• Following the transaction, Third Rock Ventures V, L.P. retains direct ownership of 6,280,525 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted via a pre-planned, automated trading program and represents a small fraction of the firm's total holdings.

Positives

• The sale was executed under a pre-planned Rule 10b5-1 program, indicating the transaction was not based on sudden material non-public information.

Negatives

• The sale represents a reduction in the equity position held by a major 10% shareholder.

Risks

• Continued selling by major institutional shareholders could exert downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that institutional venture capital firms frequently utilize Rule 10b5-1 plans to systematically divest holdings in biotech companies following IPOs or lock-up expirations, which is a standard liquidity event rather than a signal of deteriorating company fundamentals.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for venture capital firms to manage exit strategies while maintaining compliance with insider trading regulations.

Stakeholder Impact

• Shareholders should view this as a routine liquidity event for a venture capital investor.

Next Steps

• Continued monitoring of Form 4 filings to track further divestment activity by major shareholders.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Third Rock Ventures, Insider Trading, Form 4, Biotech